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STING is an endoplasmic reticulum (ER) signaling adaptor that is essential for the type I 32 
Interferon response to DNA pathogens. Aberrant activation of STING is linked to the pathology 33 
of autoimmune and autoinflammatory diseases. The rate-limiting step for the activation of 34 
STING is its translocation from the ER to the ER–Golgi intermediate compartment. Here we 35 
found that deficiency in the Ca2+ sensor STIM1 caused spontaneous activation of STING and 36 
enhanced expression of type I interferons under resting conditions in mice and a patient 37 
suffering from combined immunodeficiency. Mechanistically, STIM1 associated with STING to 38 
retain it in the ER membrane, and co-expression of full-length or a STING-interacting fragment 39 
of STIM1 suppressed the function of dominant STING mutants that cause autoinflammatory 40 
diseases. Furthermore, deficiency in STIM1 strongly enhanced the expression of type I 41 
interferons after viral infection and prevented the lethality of infection with a DNA virus in vivo. 42 
This work delineates a STIM1–STING circuit that maintains the resting state of the STING 43 
pathway.  44 
 45 
The endoplasmic reticulum (ER) provides a structural platform for activation of the type I interferon 46 
(IFN) response. Stimulator of interferon genes (STING), a key signaling adaptor protein for DNA-47 
sensing pathways localizes to the ER membrane in the resting state1, 2, 3. After activation by cytosolic 48 
DNAs, it translocates into the ER-Golgi intermediate compartment (ERGIC) to recruit TANK-binding 49 
kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3). IRF3, upon phosphorylation by TBK1, 50 
homo-dimerizes and translocates into the nucleus to induce transcription of type I IFNs4, 5, 6, 7. Beside 51 
an essential role in protecting the host against DNA pathogens, STING is also involved in the 52 
pathogenesis of autoinflammation caused by self-DNAs in murine models8, 9. Accordingly, STING has 53 
been implicated in the pathogenesis of Aicardi–Goutieres syndrome (AGS), systemic lupus 54 
erythematosus (SLE) and other type I Interferonopathies10. Furthermore, mutations in STING have 55 
been uncovered in patients with STING-associated vasculopathy with onset in infancy (SAVI) and 56 
lupus-like symptoms11, 12, 13. The STING variants found in SAVI patients are constitutively active and 57 
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localize to the ERGIC without the STING ligand, cyclic dinucleotides (CDNs), suggesting that they 58 
may escape a mechanism that potentially maintains the ER localization of STING14. Since CDNs can 59 
be generated by cytosolic self-DNAs derived from mitochondrial damage or genomic instability, and 60 
the binding affinity of STING for CDNs is high (∼5 nM for 2’,3’ cyclic guanosine monophosphate-61 
adenosine monophosphate [2’,3’-cGAMP])15, active inhibitory mechanisms are necessary to tightly 62 
control its activation. However, little is known about how the resting state of STING is maintained. 63 
High Ca2+ concentration in the ER ([Ca2+]ER) is essential for its normal function. At the same 64 
time, diverse receptors elevate cytoplasmic [Ca2+] by depleting ER Ca2+ stores through a mechanism 65 
called store-operated Ca2+ entry (SOCE). Stromal interaction molecule 1 (STIM1), an EF-hand-66 
containing Ca2+-binding protein localizes throughout the ER when [Ca2+]ER is high, but after depletion 67 
of the ER Ca2+ stores, it translocates into junctional areas between the ER and plasma membrane, 68 
interacts with the pore subunit of store-operated Ca2+ (SOC) channels; Orai1, and induces Ca2+ 69 
entry16. The essential role of STIM1 in effector function of adaptive immune cells including T and B 70 
cells has been well established17, 18, 19. Mutations in STIM1 cause severe combined immune deficiency 71 
(SCID) in humans20. Paradoxically, these patients also suffer from lymphoproliferative and 72 
autoimmune complications. Although for some forms of SCID, the mechanisms behind these 73 
complications have been worked out; for example, poor development of both central and peripheral 74 
tolerance21, the underlying causes of inflammatory complications in patients harboring mutations in 75 
STIM1 are not unknown.   76 
The role of STIM1 in cells of the innate immune system is currently unclear. Here, we 77 
examined the phenotypes of STIM1-deficient cells and observed that loss of STIM1 induces 78 
spontaneous activation of the STING-TBK1-IRF3 pathway to activate type I IFN responses under 79 
sterile conditions in both murine and human cells. Mechanistically, STIM1 directly interacted with 80 
STING to retain it in an inactive state on the ER membrane. Accordingly, we also observed strong 81 
resistance to viral infections in STIM1 KO cells and animals. These results suggest that STIM1 plays 82 
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an important role in regulation of the innate immune responses in addition to its well-established 83 
function in regulation of SOCE in adaptive immunity. 84 
Results 85 
STIM1 deficiency induces type I IFN response 86 
To gain insights into possible role of STIM1 in innate immune responses, we checked expression of 87 
various inflammatory cytokines in Stim1–/– murine embryonic fibroblasts (MEFs). Among these, 88 
transcripts of Ifnb1 and Il6 as well as interferon-stimulated genes (ISGs) were significantly increased 89 
in Stim1–/– MEFs compared to those in wild type (WT) cells (Fig. 1a). Accordingly, we observed 90 
increased amounts of secreted IFN-β protein in culture supernatants from Stim1–/– MEFs (Fig. 1b).  91 
Due to the well-established role of STIM1 in SOCE, it was possible that the increased type I IFN 92 
response in Stim1–/– MEFs was due to altered intracellular Ca2+ homeostasis. To check this possibility, 93 
we compared responses between Stim1–/– and Orai1–/– MEFs, both of which show loss of SOCE (Fig. 94 
1c). However, we did not observe enhanced Ifnb1 expression in Orai1–/– MEFs, indicating that block of 95 
SOCE or altered intracellular Ca2+ levels do not contribute to increased type I IFN response observed 96 
in Stim1–/– MEFs.  97 
To verify these observations in primary cells, we examined bone marrow-derived 98 
macrophages (BMDMs) from WT (Stim1fl/fl) and Stim1fl/flUBC-ERT2-cre mice to induce acute loss of 99 
STIM1 expression after tamoxifen treatment (Fig. 1d). Similar to MEFs, we observed enhanced 100 
expression of Ifnb1 and Il6 transcripts in Stim1–/– BMDMs. Next, we examined if this enhanced type I 101 
IFN expression phenotype was conserved in human macrophages. We generated STIM1–/– THP1 102 
cells by CRISPR/Cas9-mediated genome editing using two different gRNA sequences 103 
(Supplementary Fig. 1). Similar to murine cells, we observed an induction of IFNB1 and IL6 mRNAs 104 
and increased IFN-β secretion in STIM1–/– THP1 clones (Fig. 1e, f). Moreover, exogenous expression 105 
of STIM1 in these THP1 clones significantly rescued the phenotype by decreasing type I IFN 106 
expression. Taken together, these data strongly demonstrate an inhibitory role of STIM1 in type I IFN 107 
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responses. STIM2 is another member of the STIM family that shares 66% amino acid sequence 108 
similarity with STIM116. Both of them are ER-resident proteins, but they function differently in sensing 109 
depletion of the ER Ca2+ stores and efficacy to activate Orai channels. STIM1 plays a dominant role in 110 
activation of SOCE while STIM2 is involved in ER Ca2+ homeostasis by sensing subtle changes in 111 
[Ca2+]ER22 23. To check a possible function of STIM2 in regulation of type I IFN responses, we 112 
generated two independent STIM2–/– THP1 clones. However, neither of the STIM2 KO clones showed 113 
elevated expression of IFNB1 transcripts (Supplementary Fig. 2). Collectively, these results establish 114 
a specific role for STIM1 in regulating the resting state of the type I IFN responses in murine and 115 
human cells.  116 
 117 
STING-TBK1-IRF3 pathway links perturbation in STIM1 expression to IFN-β expression 118 
Since both STIM1 and STING, an important regulator for the type I IFN responses, localize to the ER 119 
membrane, we checked the possibility that STIM1 regulates the function of STING. Upon activation of 120 
STING via exposure to its ligand 2’,3’-cGAMP, we observed a pronounced enhancement of Ifnb1 121 
transcript and protein levels in Stim1–/–, but not Orai1–/– MEFs when compared to those in WT MEFs 122 
(Fig. 2a). This higher type I IFN response in Stim1–/– MEFs was also observed in the presence of 123 
cytosolic DNAs after transfection with IFN stimulatory DNA (ISD) or poly(dA:dT) that are known to 124 
activate the STING pathway, but not with poly(I:C), a poor agonist of the STING pathway (Fig. 2b, 125 
left). Similarly, we observed elevated transcripts of IFNB1 in STIM1–/– THP1 cells transfected with 126 
2’,3’-cGAMP, but not poly(I:C) (Fig. 2b, right).   127 
To determine whether deficiency of STIM1 induces an increase in type I IFN response through 128 
the STING-TBK1-IRF3 pathway, we checked for activated IRF3 and TBK1 in WT and Stim1–/– MEFs. 129 
We examined localization of GFP-IRF3, which was exclusively in the cytoplasm in WT MEFs but 130 
showed almost equal distribution in the cytoplasm and nuclei in Stim1–/– MEFs (Fig. 2c). 131 
Biochemically, we detected enhanced homo-dimers of IRF3, in Stim1–/– MEFs compared to WT cells 132 
under resting conditions (Fig. 2d). Furthermore, we found enhanced levels of phosphorylated TBK1 133 
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and accordingly increased ratio of p-TBK1 vs. total TBK1 in Stim1–/– MEFs, BMDMs and STIM1–/– 134 
THP1 cells (Fig. 2e). We could also detect enhanced dimerization of endogenous STING in Stim1–/– 135 
MEFs, which is considered an active form of STING (Supplementary Fig. 3a). Likewise, STIM1–/– 136 
HEK293T cells stably expressing STING also showed enhanced STING dimers and multimers 137 
(Supplementary Fig. 3b). Next, we examined whether co-deletion of STING in STIM1-deficient cells 138 
could rescue this enhanced IFN-β expression phenotype. Deletion of both Stim1 and Tmem173 (gene 139 
encoding STING) in MEFs (double knockout, DKO) dramatically reduced Ifnb1 and Il6 transcripts 140 
under resting or cGAMP-treated conditions (Fig. 2f). Co-deletion of Tmem173 also rescued increased 141 
IFN-β secretion observed in Stim1–/– MEFs treated with poly (dA:dT) (Fig. 2g). We observed very 142 
similar results using THP1 cells. Deletion of both STIM1 and TMEM173 in double knockout (DKO) 143 
THP1 cells was confirmed by immunoblotting and SOCE measurements (Fig. 2h). DKO THP1 cells 144 
showed reduced IFNB1 and IL6 mRNA levels, suggesting that the elevated cytokine expression in 145 
STIM1–/– THP1 cells were derived from increased STING activity. Together, these results suggest that 146 
the increase in type I IFN responses observed in STIM1-deficient cells is mediated by the STING-147 
TBK1-IRF3 pathway, and STIM1 plays a novel role in type I IFN signaling via regulating STING 148 
function.  149 
 150 
Increased type I IFN responses in patient lacking STIM1 expression 151 
Previously, patients showing SCID symptoms and bearing homozygous nonsense mutation of STIM1 152 
(E136X) were shown to lack STIM1 expression due to nonsense-mediated mRNA decay24. To mimic 153 
the phenotype of this patient, we transduced STIM1-deficient cells with viral vectors encoding WT and 154 
STIM1E136X proteins. We confirmed lack of STIM1 expression in Stim1–/– MEFs transduced to express 155 
STIM1E136X while those with STIM1WT showed expression similar to the endogenous protein in WT 156 
MEFs (Fig. 3a). Importantly, expression of STIM1WT but not STIM1E136X rescued the increased type I 157 
IFN response in Stim1–/– MEFs (Fig. 3b).  158 
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 To examine if this was true in STIM1-deficient patients, we harvested primary cells from a 159 
patient lacking STIM1 expression due to a homozygous STIM1 mutation c.478del, p.(Ser160fs). The 160 
lack of STIM1 expression in patient’s PBMCs was confirmed by immunoblotting (Fig. 3c). Patient 161 
serum showed enhanced IFN-β, IL-6 and TNF cytokines when compared to those observed in three 162 
healthy controls (Fig. 3d). Consistently, we also observed enhanced expression of ISGs in PBMCs 163 
and monocytes from the patient, when compared to those in two healthy controls (Fig. 3e). 164 
Interestingly, the patient also exhibited very mild SAVI-like symptoms – he suffered from 165 
desquamation and blistering with skin eruptions mainly affecting the palm, soles of the feet and 166 
cheeks. He also showed pronounced nail dystrophy25. Together, these data confirm that loss of 167 
STIM1 in humans enhances expression of type I IFN, proinflammatory cytokines and ISGs, similar to 168 
murine cells. 169 
 170 
STIM1 interacts with STING for its retention at the endoplasmic reticulum 171 
The increased type I IFN response together with higher basal activity of the STING-TBK1-IRF3 172 
pathway in STIM1-deficient cells suggests that STIM1 may be involved in maintaining the resting state 173 
of the STING pathway. Microscopy analysis showed a strong co-localization between STIM1 and 174 
STING in the ER (Fig. 4a). Hence, we checked if STIM1 can physically interact with STING to retain it 175 
in the ER. When co-expressed in HEK293T cells, STIM1 was specifically identified from 176 
immunoprecipitates of STING (Fig. 4b). In addition, we also validated association between 177 
endogenous STIM1 and STING proteins by immunoprecipitation (Fig. 4c). This association was 178 
specific because another ER-resident protein, calnexin could not be detected in immunoprecipitates of 179 
STIM1.   180 
Next, we examined association between STIM1 and STING upon activation of either of the 181 
proteins. We activated STIM1 by treatment with thapsigargin that depletes the ER Ca2+ stores, and 182 
activated STING using its ligand, 2’,3’-cGAMP. We observed reduced biochemical association 183 
between the two proteins by stimulation of either STIM1 or STING (Fig. 4d). These data indicate that 184 
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STING and STIM1 form a protein complex that is dissociated due to conformational changes induced 185 
by stimulation of either of these proteins. Association between STING and STIM1 prompted us to 186 
check for a possible role of STING in regulating the function of STIM1. We observed reduced SOCE 187 
induced by thapsigargin or anti-CD3 antibody treatment in HEK293T and Jurkat T cells 188 
overexpressing STING (Supplementary Fig. 4a, b, c). In addition, we observed enhanced STIM1 189 
translocation to the ER-PM junctions in thapsigargin treated STING-deficient (Tmem173–/–) MEFs 190 
(Supplementary Fig. 4d). Conversely, there was significant enhancement of SOCE in TMEM173–/– 191 
Jurkat cells (Supplementary Fig. 4e, f). This enhancement was not observed in THP1 cells, indicating 192 
cell type specificity (Fig. 2h). Taken together, these data show that association with STING impacts 193 
the function of STIM1 in mediating SOCE.  194 
STING contains four transmembrane (TM) segments in its N terminus that span the ER 195 
membrane (Fig. 4e)1. STING N-terminal domain (NTD) containing the TM segments plays an 196 
important role in its ER localization, trafficking and interaction with regulators including ZDHHC1, 197 
AMFR, TRIM32, and RNF526, 27, 28, 29. Tumor DNA viral proteins, E1A and E7 also bind to STING NTD 198 
to inhibit downstream signaling28. The cytoplasmic region (C-terminal domain, CTD) of STING 199 
contains the dimerization domain (DD), CDN-binding region, and the C-terminal tail (CTT) that 200 
interacts with TBK1 and IRF3. STIM1 has an N-terminal ER-luminal region containing the Ca2+-201 
sensing EF-hand motifs and sterile alpha motif (SAM) domain that is important for its multimerization 202 
after ER Ca2+ depletion. It also has a single TM domain that traverses the ER membrane. The 203 
cytoplasmic C terminus contains multiple functional domains including coiled-coil domains (CC) 1, 204 
CC2, CC3, a serine/threonine-rich domain (S/T), and a lysine-rich domain (poly-K) that are important 205 
for binding to the plasma membrane after depletion of ER Ca2+ stores. A fragment containing CC2 206 
and CC3 of STIM1 called the CRAC activation domain (CAD) or the STIM1 Orai activating region 207 
(SOAR) was identified to interact directly with Orai1 subunits to gate them16, 29. 208 
To determine their interaction domains, we carried out co-immunoprecipitation using lysates of 209 
HEK293T cells overexpressing full-length, NTD or CTD of STING together with full-length STIM1. 210 
9 
 
These results showed NTD of STING as a major STIM1-interacting domain while its CTD interacted 211 
weakly with STIM1 (Fig. 4f, left panels). To uncover the domain(s) of STIM1 involved in interaction 212 
with STING, we performed GST pull-down experiments by incubating bacterially purified GST-fused 213 
fragments of STIM1 with lysates of HEK293T cells overexpressing full-length, NTD or CTD of STING. 214 
From this analysis, we identified a predominant interaction between the N terminus of STIM1 215 
containing the TM segment (a.a. 1-249) and STING NTD, and a weaker binding of the cytoplasmic 216 
fragment predominantly containing the S/T-rich region of STIM1 to STING CTD (Fig. 4f, right panels). 217 
These data suggest that interaction between STIM1 and STING is predominantly mediated by their 218 
TM domains on the ER membrane with weak additional interactions between their cytoplasmic 219 
regions.  220 
 221 
STIM1 acts as an ER retention factor to suppress the activity of STING 222 
Ligand binding induces conformational rearrangement and trafficking of STING from the ER to the 223 
ERGIC and the Golgi apparatus14, 30, 31.  Since STIM1 interacted strongly with STING NTD, which is 224 
crucial for STING localization, we hypothesized that STIM1 may control the ER localization of STING. 225 
To validate this hypothesis, we examined the localization of STING in WT and Stim1–/– MEFs by co-226 
staining with ERGIC marker (ERGIC-53/p58). We observed a significant population of Stim1–/– MEFs 227 
showing partial localization of STING at the ERGIC without any stimulation, and this population 228 
increased much faster in Stim1–/– MEFs infected with the DNA virus, herpes simplex virus type-1 229 
(HSV-1) when compared to WT MEFs (Fig. 5a).  To check how interaction with STIM1 influences the 230 
function of STING, we monitored the translocation kinetics of STING after treatment of WT or Stim1–/– 231 
MEFs with 2’,3’-cGAMP and observed faster translocation of STING into the ERGIC in Stim1–/– MEFs 232 
than in WT cells (Fig. 5b). Together with our biochemical analysis, these data suggest that STIM1 233 
physically interacts with STING to promote its retention onto the ER membrane. 234 
We checked if overexpression of STIM1 can inhibit the function of STING using Ifnb promoter-235 
driven luciferase reporter (IFN-Luc) assays after 2’,3’-cGAMP treatment. In cells co-expressing STING 236 
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and increasing amounts of full length or the N- and C-terminal binding fragments of STIM1, we 237 
observed a dose-dependent inhibition of luciferase reporter expression (Fig. 5c). In support of our 238 
biochemical analyses, the N-terminal TM-containing fragment of STIM1 (a.a. 1-249) showed a 239 
stronger inhibition of luciferase reporter activity than the cytoplasmic domain (a.a. 400-600) while 240 
STIM1 fragments (a.a. 250-400 and a.a. 600-685) that do not interact with STING did not affect 241 
luciferase activity. Of note, expression of full-length STIM1 or its N-terminal fragment (a.a. 1-249) did 242 
not influence the luciferase activity when stimulated with poly(I:C). These data validate functional 243 
interaction between STIM1 and STING proteins.  244 
The genetic lesions of patients exhibiting autoinflammatory vasculopathy and autoimmunity 245 
were mapped to single amino acid substitutions in STING11. These substitution mutations changed 246 
one of the conserved residues V147, N154, or V155, all of which are localized in or around the STING 247 
dimerization domain32. In addition, these substitutions lead to localization of STING at the ERGIC and 248 
constitutive TBK1 and IRF3 activation and uncontrolled type I IFN response11, 13. We examined if 249 
these disease-associated STING mutants retained binding to STIM1. Using immunoprecipitation 250 
analysis, we observed reduced interaction of the STING SAVI mutants with STIM1 and 251 
overexpression of full-length or N-terminal fragment of STIM1 could suppress Ifnb promoter-driven 252 
luciferase activity of these mutants. (Supplementary Fig. 5a, b). In support of these data, confocal 253 
analyses showed a partial block of constitutive ERGIC localization of these mutants in the presence of 254 
STIM1 (Supplementary Fig. 5c). Collectively, these results confirm the previous observations that exit 255 
from the ER is an important step for the activation of STING and STIM1 can block this trafficking via 256 
direct interaction.  257 
 258 
Genetic inhibition of STIM1 expression primes antiviral activity 259 
We sought to determine whether deficiency of STIM1 influences activation of the type I IFNs in 260 
response to DNA virus infection. To examine this, WT and Stim1–/– MEFs were infected with DNA 261 
viruses (e.g., HSV-1 and murine γ-herpesvirus, MHV-68). Spontaneous induction of IFN-β observed in 262 
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Stim1–/– MEFs was substantially increased after HSV-1 infection (Fig. 6a). We also observed a 263 
marked reduction in expression of GFP, encoded from the viral genome which served as an indicator 264 
for viral replication in Stim1–/– MEFs. We observed similar results using another DNA virus, MHV-68. 265 
Similar to HSV-1 infection, MHV-68-infected Stim1–/– MEFs showed much lower expression of the 266 
viral genome-driven GFP, as well as early and late phase viral transcripts (e.g., ORF57 and ORF29, 267 
respectively), indicative of a lower viral burden (Fig. 6b). In consistence with these data, Stim1–/– 268 
MEFs showed enhanced phosphorylation of IRF3 upon HSV-1 infection (Fig. 6c). We observed 269 
similar results in primary cells, where Stim1–/– BMDMs showed enhanced expression of Ifnb1 and Il6 270 
mRNAs under resting conditions, as well as after HSV-1 infection (Fig. 6d). Together, these data 271 
show that loss of STIM1 increases resistance to DNA virus infections.  272 
Next, we validated these observations in STIM1–/– THP1 macrophages. Similar to data with 273 
mouse cells, STIM1 deficiency rendered human macrophages resistant to HSV-1, decreasing 274 
expression of GFP as observed by microscopy and transcript analyses (Fig. 6e). Accordingly, we 275 
observed enhanced expression of IFNB1 transcripts in STIM1–/– THP1 cells. Previously, it was shown 276 
that anti-viral immunity against HIV infection also relies on the cGAS-STING pathway due to the 277 
presence of cytosolic DNA generated by reverse-transcription8, 33. To investigate whether STIM1 278 
deletion imparts resistance to HIV, we infected wild type and STIM1–/– THP1 cells with GFP-HIV and 279 
observed a dramatic reduction of HIV infection in STIM1–/– THP1 cells as judged by frequency of 280 
GFP+ cells (Fig. 6f). Together, these results suggest that deficiency of STIM1 can prime host 281 
response against infection with DNA viruses and retroviruses in various murine and human cell types.  282 
Many DNA viruses, including HSV-1 are known to activate Ca2+ signaling for a productive 283 
infection34. Hence it is possible that resistance to DNA virus infection in Stim1–/– MEFs may be due to 284 
loss of SOCE. To determine the contribution of SOCE versus enhanced STING activity in host 285 
resistance to DNA virus infection, we compared responses of Stim1–/– and Orai1–/– MEFs to HSV-1 286 
infection. We observed a moderate resistance to HSV-1 infection in Orai1–/– MEFs, but in comparison, 287 
the resistance to HSV-1 infection was approximately 100-fold more pronounced in Stim1–/– cells 288 
12 
 
(Supplementary Fig. 6a). In support of the SOCE-independent role of STIM1 in regulation of STING 289 
function, we found that Ifnb1 mRNA expression was not increased after HSV-1 infection in Orai1–/– 290 
cells contrary to Stim1–/– cells. Finally, Stim1–/– MEFs when treated with inhibitor of the IFN receptor-291 
JAK-STAT pathway, tofacitinib, became susceptible to HSV-1 infection (Supplementary Fig. 6b). 292 
Together, these results indicate a predominant role of the type I IFN pathway in the resistance of 293 
STIM1-deficient cells to viral infections.  294 
 295 
Ablation of STIM1 primes type I IFN response in vivo 296 
To gain insight into the importance of STIM1 in host defense against viral infection in vivo, we 297 
investigated the antiviral immune response in Stim1fl/fl and Stim1fl/flLyz2-cre mice. In parallel, to 298 
compare the contribution of SOCE in host resistance to viral infections, we generated conditionally 299 
targeted Orai1 animals (Supplementary Fig. 7a), which were bred with Lyz2-cre for two generations. 300 
BMDMs differentiated from bone marrows of Orai1fl/flLyz2-cre animals showed almost a complete loss 301 
of Orai1 transcripts and SOCE (Supplementary Fig. 7b, c). Since HSV-1 is a neurotropic virus and the 302 
leading cause of sporadic viral encephalitis, we investigated the effects of Orai1 and Stim1 deficiency 303 
on HSV-1-induced lethality and viral loads in the brain. When infected with HSV-1 intravenously, 304 
control (Stim1fl/fl and Orai1fl/fl) as well as Orai1fl/flLyz2-cre animals showed susceptibility and died 305 
within 6-8 days of infection (Fig. 7a, b). In contrast Stim1fl/flLyz2-cre mice were completely resistant to 306 
HSV-1-induced lethality, and accordingly, recovered from loss of body weight. Viral titers in the brains 307 
obtained from Stim1fl/flLyz2-cre mice were significantly lower than Stim1fl/fl animals (Fig. 7c). 308 
Importantly, serum cytokine measurements showed elevated levels of serum IFN-β, IL-6 and TNF in 309 
uninfected as well as HSV-1-infected Stim1fl/flLyz2-cre mice, when compared to littermate controls 310 
(Fig. 7d). Taken together, our data indicate that genetic deletion of Stim1 but not Orai1 can impart 311 
protection from HSV-induced encephalitis and lethality, due to pre-activation of the STING-mediated 312 
type I IFN signaling pathway.  313 
 314 
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Discussion 315 
STING and STIM1 commonly contain transmembrane domain(s) in their N termini and predominantly 316 
localize to the ER membrane. Co-immunoprecipitation experiments showed an association between 317 
the two proteins, that was primarily mediated by their N-terminal transmembrane domains. We 318 
showed that loss of STIM1 renders cells and mice strongly resistant to viral infections due to 319 
enhanced expression of type I IFNs and pro-inflammatory cytokines. Importantly, a patient with a 320 
mutation in STIM1 that abrogated STIM1 expression also showed elevated cytokines and ISGs. 321 
Furthermore, some of the patient’s clinical features, principally the skin and nail manifestations 322 
resemble that of SAVI patients, suggesting that the excessive type I IFNs do have adverse biological 323 
manifestation in this condition25. Mechanistically, enhanced translocation and dimerization of STING 324 
by STIM1 deficiency suggest that STIM1 may preferentially bind to STING monomers at the ER to 325 
prevent its spontaneous activation.  Conversely, we also found that STING deficiency augmented 326 
translocation of STIM1 and Ca2+ entry triggered by depletion of ER Ca2+ stores. Therefore, our studies 327 
suggest that physical and functional association between STIM1 and STING is crucial for 328 
maintenance of the resting state of both pathways.  329 
We showed that enhanced type I IFN expression in STIM1-deficient cells is not mediated by 330 
Ca2+ signaling by comparative studies with Orai1-deficient cells and animals. STIM1 deficiency made 331 
cells and mice strongly resistant to HSV-1 infections. Since many viruses including HSV-134, require 332 
elevated Ca2+ levels for their replication, we determined the contribution of the Ca2+-dependent (i.e., 333 
decreased SOCE) vs. Ca2+-independent mechanisms (i.e., enhanced type I IFN response) involved in 334 
anti-viral immunity in STIM1-deficient cells using two independent molecular tools, Orai1–/– cells/mice 335 
and JAK inhibitors. These results suggest that decreased viral burden in STIM1-deficient cells and 336 
mice is predominantly derived from enhanced type I IFN responses. Whether the same principle can 337 
be applied to other viruses with various degrees of dependence on Ca2+ signaling and activation of 338 
the STING pathway needs further studies.  339 
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Although much is understood regarding the mechanisms underlying activation of STING 340 
including ligand binding, trafficking and interaction with downstream effector molecules, little is known 341 
about regulation of its resting state. Multiple mechanisms underlying STING inhibition have been 342 
uncovered due to the importance of timely inactivation of the type I IFN signaling pathway. NLRX1 343 
and ATG9a have been shown to inhibit STING-TBK1 interaction26, 27. In addition, K48-linked 344 
polyubiquitination by RNF5 and TRIM30a results in STING degradation after ligand binding35, 36. All 345 
these inhibitory mechanisms target STING function after ligand binding and trafficking. However, 346 
inhibition of STING trafficking by brefeldin A, an inhibitor of ADP ribosylation factor (ARF) GTPases, 347 
blocks activation of the downstream pathway, suggesting that trafficking of STING is crucial for its 348 
function14. Consistently, our studies reveal a novel mechanism of regulation of STING activity, 349 
inhibition of STING trafficking via direct interaction with STIM1. Activity of three of the disease-350 
associated STING variants; V147L, N154S, and V155M was suppressed by STIM1 in part via 351 
blocking their translocation to the ERGIC, demonstrating a therapeutic potential of our finding. In 352 
summary, our study identifies STIM1 as an “ER retention factor” to maintain ER residency and 353 
inactive conformation of STING. Further, it suggests that one of the primary functions of CDN binding 354 
to STING is to disrupt its association with STIM1 that would allow exit of STING from the ER. Further 355 
dissection of the mechanisms underlying maintenance of the resting state of STING may inform the 356 
design of specific therapeutic strategies geared towards enhancement/inhibition of STING activity in 357 
the context of vaccination and sterile inflammatory diseases (e.g., AGS and SAVI), respectively. 358 
 359 
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Figure Legends  501 
Figure 1. STIM1 deficiency spontaneously induces type I IFN response in murine and human 502 
cells. a, Representative immunoblot showing expression of STIM1 in wild type (WT) and Stim1–/– 503 
MEFs (left). qPCR analysis of indicated cytokines and ISGs in unstimulated indicated MEFs (right). 504 
qPCR data show pooled technical replicates from two independent experiments (Ifnb1 and Il6) and 505 
one representative triplicate from two independent experiments (other genes). b, Levels of secreted 506 
IFN-β from culture supernatants of unstimulated WT or Stim1–/– MEFs. c, Representative traces 507 
showing averaged SOCE from WT (31 cells), Orai1–/– (30 cells) and Stim1–/– (29 cells) MEFs after 508 
passive depletion of intracellular Ca2+ stores with 1 μM thapsigargin (TG) in the presence of external 509 
solution containing 20 mM Ca2+ (left). Bar graph (middle) shows averaged baseline subtracted SOCE 510 
(± s.e.m.) from four independent experiments. right: qPCR analysis of Ifnb1 mRNA in indicated MEFs. 511 
d, Representative immunoblot showing expression of STIM1 in BMDMs (left). qPCR analysis of Ifnb1 512 
and Il6 mRNA in unstimulated WT and Stim1–/– BMDMs (right). e, Immunoblot showing expression of 513 
STIM1 in wild type (WT) and STIM1–/– THP1 cells generated using two independent sgRNAs (sg#2) 514 
and 3 (sg#3). qPCR analysis of IFNB1 and IL6 mRNA in unstimulated WT, STIM1–/– THP1 cells and 515 
those reconstituted for expression of STIM1 (right two panels).  f, Secreted IFN-β levels from culture 516 
supernatants of untreated or PMA-differentiated WT or STIM1–/– THP1 cells. Data show 517 
representative triplicate from two independent experiments (panels b, e and f) or pooled technical 518 
replicates from two (c) or three (d) independent experiments. All immunoblot data (panels a, d and e) 519 
are representative of three independent experiments with similar results. Data are shown as mean ± 520 
s.e.m. *p < 0.005, and **p < 0.0005 (unpaired/two-tailed t test – a, b, d; One-way ANOVA – c; and 521 
Two-way ANOVA – e).  522 
 523 
Figure 2. STING-TBK1-IRF3 pathway links loss of STIM1 expression to Ifnb1 transcription. a, 524 
qPCR analysis of Ifnb1 mRNA in indicated MEFs under resting conditions or after stimulation with 525 
2’,3’-cGAMP for 2 or 4 h (left). Numbers on top indicate average fold change relative to WT MEFs. 526 
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Secreted IFN-β levels from culture supernatants of indicated MEFs after stimulation with 2’,3’-cGAMP 527 
(right). Data show pooled technical replicates from two independent experiments (qPCR) or one 528 
representative triplicate from two independent experiments (ELISA) with similar results. b, qPCR 529 
analysis of Ifnb1 transcripts in indicated MEFs transfected with interferon stimulatory DNA (ISD), 530 
poly(dA:dT) or poly (I:C) for indicated time (left). qPCR analysis of IFNB1 mRNA from untreated or 531 
indicated nucleic acid-transfected THP1 cells. c, Representative confocal images showing localization 532 
of GFP-IRF3 in indicated MEFs. Bar graph below depicts quantification from indicated number of 533 
cells. Scale bars, 5 μm. d, Representative immunoblot for detection of IRF3 under non-reducing 534 
conditions in DSP-crosslinked indicated MEFs, (left). Bar graph (right) shows densitometry analysis of 535 
IRF3 ratio (dimer/monomer) from three independent experiments. e, Representative immunoblots 536 
showing expression of phospho-TBK1 (P-TBK1), total TBK1, and ߚ-actin from indicated cells. 537 
Numbers below indicate normalized fold change in ratio of P-TBK1/total TBK1. f, Representative 538 
immunoblots showing expression of STIM1 and STING in WT, Stim1–/–, or Stim1–/– and Tmem173–/– 539 
double knock out (DKO) MEFs (left). Expression of Ifnb1 and Il6 transcripts in indicated MEFs under 540 
resting conditions (left two panels) or 4 h after stimulation with 2’,3’-cGAMP (right two panels). g, 541 
Secreted IFN-β levels from culture supernatants of indicated MEFs after stimulation with indicated 542 
nucleic acids. h, Representative immunoblots showing expression of STIM1 and STING in WT, 543 
STIM1–/–, TMEM173–/– or STIM1–/– and TMEM173–/– double knock out (DKO) THP1 cells (left). 544 
Representative traces of averaged SOCE from WT (33 cells), STIM1–/–, (30 cells), TMEM173–/– (31 545 
cells) and DKO (31 cells) THP1 cells after passive depletion of intracellular Ca2+ stores with 1 μM 546 
thapsigargin (TG) in the presence of external solution containing 2 mM Ca2+ (middle). Bar graph 547 
shows averaged baseline subtracted SOCE (± s.e.m.) from three independent experiments. Right 548 
panels show qPCR analysis of IFNB1 or IL6 mRNA in indicated THP1 cells. Data show representative 549 
triplicates from two independent experiments with similar results (b, d, f, g and h) unless indicated. All 550 
immunoblots are representative of at least three independent experiments with similar results. Data 551 
are shown as mean ± s.e.m. *p < 0.05, **p < 0.005, ***p < 0.0005 [Two-way ANOVA – a (left panel); 552 
unpaired/two-tailed t test – a (right panel), b; Chi-square test – c; and One-way ANOVA – d, f, g, h].   553 
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Figure 3. STIM1 deficiency causes enhanced type I IFN response in patient cells. a, 554 
Representative immunoblot showing expression of STIM1 in WT, Stim1–/– MEFs or those expressing 555 
either WT STIM1 (+STIM1) or STIM1E136X (+E136X) mutant. b, qPCR analysis of Ifnb1 and Il6 mRNA 556 
in indicated MEFs under resting conditions or 2 h after stimulation with 2’,3’-cGAMP. Data show 557 
representative triplicate from two independent experiments. c, Representative immunoblot showing 558 
expression of STIM1 and GAPDH in PBMCs isolated from a healthy control (HC) and patient (Pat.). d, 559 
Levels of indicated cytokines in serum samples from healthy controls (three independent donors) and 560 
STIM1-deficient patient. Data show one representative triplicate from two independent experiments 561 
(n=9 for three HCs). e, Taqman qPCR analysis of indicated ISGs from peripheral blood mononuclear 562 
cells (PBMCs, top) or purified monocytes (below) from two independent healthy controls and STIM1-563 
deficient patient. Patient data (normalized to those of healthy controls) are derived from two 564 
independent experiments performed in duplicates. Data are shown as mean ± s.e.m. *p < 0.05, **p < 565 
0.005, ***p < 0.0005 (One-way ANOVA – b; and unpaired/two-tailed t test – d, e).  566 
 567 
Figure 4. STIM1 interacts with STING for its retention in the endoplasmic reticulum. a, 568 
Representative confocal microscopy image of STING-GFP and STIM1 in a MEF cell. Scale bar, 5 µm, 569 
Inset – 1 µm. Pearson’s r = 0.67 ± 0.08 from 9 cells. b, FLAG-immunoprecipitates (IP) from lysates of 570 
HEK293T cells overexpressing FLAG-tagged STING and His-tagged STIM1 were immunoblotted for 571 
detection of STIM1. Arrow, monomeric STING or STIM1; *, STING multimers. c, Immunoprecipitates 572 
of endogenous STING from HEK293 cells were immunoblotted for detection of indicated proteins. d, 573 
FLAG-immunoprecipitates (IP) from lysates of HEK293T cells expressing FLAG-tagged STING and 574 
His-tagged STIM1 with or without treatment with thapsigargin (1 μM, 10 min; left) or 2’, 3’-cGAMP (1 575 
μM, 30 min and further incubation in media for 1 h) were immunoblotted for detection of the indicated 576 
proteins. Bar graphs show densitometry analysis of normalized fold changes (mean ± s.e.m.) in 577 
STIM1 and STING band intensity from three (left) and four (right) independent experiments. e, 578 
Schematic showing domain structure of STING and STIM1 as indicated in the text. Amino acid 579 
22 
 
residues of STING and STIM1 fragments used in this study are indicated. f, Left – FLAG-580 
immunoprecipitates (IP) from lysates of HEK293T cells expressing FLAG-tagged full-length STING 581 
(FL), NTD (a.a. 1-140), and CTD (a.a. 140-379) were immunoblotted for detection of STIM1. Right – 582 
Purified recombinant GST-fused indicated fragments of STIM1 incubated with lysates of HEK293T 583 
cells expressing FLAG-tagged, FL, NTD or CTD of STING were immunoblotted with anti-FLAG 584 
antibody. Immunoblots in panels b, c, and f are representative of four independent experiments. *p < 585 
0.005 (unpaired/two-tailed t test - d).  586 
 587 
Figure 5. STIM1 inhibits STING trafficking to the ER-Golgi intermediate compartment. a, 588 
Representative confocal microscopy images of WT or Stim1–/– MEFs stably expressing STING-GFP 589 
under resting conditions (top two panels) or 4 h after HSV-1 infection (bottom 3 panels) and stained 590 
for endogenous p58 (ERGIC). Scale bars, 10 µm. Bar graph shows quantification of indicated number 591 
of cells showing STING translocation to the ERGIC under resting conditions or after infection with 592 
HSV-1 for indicated times. Data are derived from two independent experiments. b, Representative live 593 
cell epifluorescence images of WT (top) or Stim1–/– (bottom) MEFs after treatment with 1 µM 2’, 3’-594 
cGAMP for the indicated times showing translocation of STING-GFP into the ERGIC (left). Line graph 595 
on the right shows normalized rate of translocation of STING in WT (9 cells) and Stim1–/– (11 cells) 596 
MEFs from two independent experiments. Scale bar, 10 µm. c, Reporter assays for Ifnb1 promoter 597 
activity in HEK293T cells transfected with STING and increasing amounts of full length STIM1 or its 598 
indicated fragments, 6 hours after stimulation with 2’, 3’ cGAMP (top) or poly(I:C) (below). Data show 599 
representative triplicate from two independent experiments. *p < 0.005, **p < 0.0005 Chi square test 600 
(a) and one-way ANOVA (c); N.S. – not significant. 601 
 602 
Figure 6. Ablation of STIM1 enhances host defense towards DNA viruses and HIV by priming 603 
type I IFN responses. a, qPCR analysis of Ifnb1 and GFP transcripts in uninfected or HSV-1-GFP-604 
infected (MOI 0.1, 24 h) WT or Stim1–/– MEFs. Data show pooled technical replicates from two 605 
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independent experiments. b, qPCR analysis of GFP and indicated viral mRNAs in MHV-68-GFP-606 
infected (MOI 0.2, 24 h) WT or Stim1–/– MEFs. Data show pooled technical replicates from three 607 
independent experiments. c, Representative immunoblots showing expression of phospho-IRF3 (P-608 
IRF3), total IRF3, and ߚ-actin from untreated or HSV-1-infected (MOI 5.0) WT or Stim1–/– MEFs for 609 
indicated time points.  d, qPCR analysis of Ifnb1 and Il6 mRNA in untreated or HSV-1-GFP-infected 610 
(indicated MOI, 24 h) WT or Stim1–/–  BMDMs. Data shows representative triplicate from two 611 
independent experiments. e, Top two panels show representative GFP images in HSV-1-GFP-612 
infected (MOI 10, 24 h) WT, (left) and STIM1–/– (right) THP-1 cells. Below: qPCR analysis of IFNB1 613 
and GFP transcripts from the same cells. Scale bars, 10 µm. Data shows representative triplicate from 614 
two independent experiments. f, Representative flow plots showing frequency of HIV-GFP-infected 615 
WT (left) or two different STIM1–/– (right two panels) THP1 cell lines (MOI 2.0, 24 h). Bar graph shows 616 
averaged frequency of HIV-GFP-positive indicated THP1 cell lines in the presence or absence of HIV 617 
reverse transcriptase inhibitor azidothymidine (AZT, 5 µM) from four independent experiments. 618 
Immunoblots in panel c and epifluorescence images in panel e are representative of three and two 619 
independent experiments respectively. *p < 0.005 and **p < 0.0005 [Two-way ANOVA – a (left panel), 620 
d, e (right panel), f; unpaired/two-tailed t test – a (right panel), b; One-way ANOVA – e (left panel)]. 621 
 622 
Figure 7. STIM1 deficiency enhances host defense against HSV-1 infection in vivo. a, Kinetics of 623 
survival (top) and body weight changes (bottom) of indicated numbers of control (Stim1fl/fl) and STIM1-624 
deficient (Stim1fl/flLyz2-cre) mice (6-7-week old) after intravenous injection with HSV-1 (1 x 107 PFU 625 
per mouse). b, Kinetics of survival (top) and body weight changes (bottom) of indicated numbers of 626 
control (Orai1fl/fl) and Orai1-deficient (Orai1fl/flLyz2-cre) mice after intravenous injection with HSV-1 (1 627 
x 107 PFU per mouse). Mice that lost >20% body weight were euthanized. c, Virus load in control 628 
(Stim1fl/fl) and STIM1-deficient (Stim1fl/flLyz2-cre) mouse brains 3 days after intravenous injection with 629 
HSV-1. d, ELISA analyses of the indicated cytokines from the sera of control (Stim1fl/fl) and Stim1-630 
deficient (Stim1fl/fl Lyz2-cre) mice after intravenous injection with HSV-1 for indicated times. Data in 631 
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panels a and b are pooled from two independent experiments. Panels c and d show mean +/- s.e.m. 632 
from indicated number of animals (each symbol represents data from individual animal). *p < 0.05, **p 633 
< 0.005, ***p < 0.0005 (unpaired/two-tailed t test).  634 
  635 
 636 
  637 
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Methods 638 
Chemicals and Antibodies. Fura 2-AM (F1221) was purchased from ThermoFisher Scientific. 639 
Thapsigargin and ionomycin were purchased from EMD Millipore. Poly(I:C) (P1530) was purchased 640 
from Millipore Sigma. Poly(dA:dT) (tlrl-patn) and 2’,3’-cGAMP (tlrl-nacga23) were purchased from 641 
InvivoGen. Tofacitinib (S500110MG) was purchased from Selleck Chemical LLC. Antibodies for 642 
detection of STIM1 (5668S), phosphor-IRF3 (29047S), IRF3 (4302S), phosphor-TBK1 (5483S), total 643 
TBK1 (3504S), STING (13647S), 6xHis tag (12698S), and STIM2 (4917S) were purchased from Cell 644 
Signaling Technologies. Antibodies for detection of FLAG tag (F3040), p58 (ERGIC marker, E1031) 645 
and human Orai1 (AB9868) were purchased from Millipore Sigma. Antibody for detection of  β-actin 646 
(sc-47778) was obtained from Santa Cruz Biotechnology and antibodies for detection of STIM1 (clone 647 
5A2) and GAPDH (GTX100118) from human PBMCs were obtained from Sigma and GeneTex 648 
respectively.  649 
Plasmids and cells. STIM1-YFP plasmid has been described previously37. Human STIM1 cDNA was 650 
subcloned into a lentiviral vector, FGllF (kind gift from Dr. Dong Sun An, UCLA) with a C-terminal 651 
FLAG tag and pcDNA 3.1 mychis plasmid. GST-tagged truncated fragments of STIM1 corresponding 652 
to amino acids 1-249 (containing the EF-hand, SAM domain and transmembrane segment), 250–400 653 
(containing coiled-coil domains 1 and 2), the CAD domain (amino acids 342–448), 400–600 (the 654 
serine and threonine-rich region), and 600–685 (the C-terminal PIP2-interacting domain) have been 655 
previously described37. Fragments of STING corresponding to the N-terminal TM domain (a.a. 1-154) 656 
and C-terminal domain (a.a. 149-379), both tagged with a FLAG tag in the C-terminus, were 657 
subcloned into pMSCV-CITE-eGFP-PGK-Puro vector. Full-length cDNA of human STING and SAVI 658 
mutants corresponding to V147L, N154S and V155M were subcloned into pEGFPN1 vector to 659 
generate a C-terminal GFP fusion protein and into pMSCV-CITE-eGFP-PGK-Puro vector that 660 
encodes a C-terminal FLAG tag using primers described in Supplementary Table 1. Oligonucleotides 661 
encoding sgRNAs to delete STIM1, STIM2 and STING were subcloned into lentiGuide-Puro vector 662 
(Addgene, #52963). HEK293T, Vero and Jurkat E6-1 T cell lines were obtained from American Type 663 
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Culture Collection center (ATCC, Manassas, VA). WT and Stim1-/- MEFs were generated by breeding 664 
Stim1fl/fl mice (Jackson Laboratory, stock No. 023350) with CMV-cre mice (Jackson Laboratory, stock 665 
No. 006054). MEFs were established using standard protocols from E14.5 embryos and retrovirally 666 
transduced with SV40 large T antigen in a plasmid encoding hygromycin resistance for 667 
immortalization. Orai1-/- MEFs have been previously described38.  668 
Cell Culture. MEFs, Vero and HEK293T cells were grown in complete DMEM (Mediatech) 669 
supplemented with 10% (v/v) fetal bovine serum (Hyclone), 2 mM L-glutamine (Mediatech), 10 mM 670 
HEPES (Mediatech) and Penicillin/Streptomycin (Mediatech) at 37°C and 5% CO2. BMDMs were 671 
differentiated from bone marrow cells isolated from femur and tibia of 6-8-week-old mice. For 672 
preparation of BMDMs, the bone marrow cells were cultured in 10% M-CSF-containing conditional 673 
medium from HEK293T cells expressing recombinant M-CSF (a kind gift from Stephen Smale lab, 674 
UCLA) for 4-6 days. BMDMs were cultured in the absence of M-CSF for at least 24 hours prior to 675 
experimental use. THP1 and Jurkat T cells were cultured in RPMI (Mediatech) containing 10% fetal 676 
bovine serum (Hyclone). Cells were infected with indicated MOIs of indicated viruses and harvested in 677 
TRIzol Reagent for transcript expression analysis. For 2’,3’-cGAMP treatment, MEFs or HEK293T 678 
cells were treated with or without 1 μM 2’,3’-cGAMP for 30 mins in digitonin permeabilization buffer 679 
(50 mM HEPES, 100 mM KCl, 3 mM MgCl2, 0.1 mM DTT, 85 mM sucrose, 0.2% BSA, 1 mM ATP, 0.1 680 
mM GTP, pH 7.0) followed by culture medium for indicated times, after which the cells were harvested 681 
for transcript analysis or reporter assays. MEFs were transfected with 5 μg of interferon stimulatory 682 
DNA (ISD39), polydA:dT or poly I:C using Lipofectamine 2000 (Thermofisher Scientific). For ELISAs, 683 
MEFs were treated with cGAMP as described and supernatant harvested after 24 hrs.  684 
Mice. Stim1fl/fl animals were purchased from Jackson Laboratory (stock No. 023350) and bred with 685 
Lyz2-cre animals (Jackson Laboratory, stock No. 004781) for two generations. Targeting of murine 686 
Orai1 was performed by flanking exon 2 with LoxP sites by homologous recombination in AB2.2 687 
(129SvEv) embryonic stem (ES) cells. Exon 2 encodes for 201 a.a. out of a total of 304 a.a. of Orai1 688 
protein. G418-resistant clones were screened by PCR for homologous recombination at both 689 
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homology arms. Chimeric mice with floxed Orai1 alleles were generated by blastocyst injection of 690 
heterozygous Orai1fl/+ ES cell clones. Founder Orai1fl/+ mice were bred with Flp-deleter mice (Jackson 691 
Laboratory) to remove the neomycin resistance gene cassette. Orai1fl/fl mice were backcrossed to 692 
C57/BL6/J mice for at least 10 generations and then bred with Lyz2-cre mice to generate myeloid-693 
specific deletion of Orai1. All mice were maintained in pathogen-free barrier facilities and used in 694 
accordance with protocols approved by the Institutional Animal Care and Use Committee at the 695 
UCLA.  696 
Patient. Sample collection from the patient was performed after obtaining written consent from his 697 
parents according to the principles of the Declaration of Helsinki and after local ethics approval. 698 
Detailed clinical evaluation was undertaken in appropriate clinical setting. PBMC isolation from 699 
healthy control and patient human blood samples was performed by gradient separation using 700 
Lymphoprep (Stem Cell Technologies). Monocytes were purified from PBMCs using a Monocytes 701 
separation kit II (# 130-091-153, Miltenyi Biotec). The patient is a 4-year-old boy of consanguineous 702 
Pakistani background, who initially presented to paediatric neurology due to poor mobility. A diagnosis 703 
of STIM1 deficiency was made following referral to paediatric immunology due to recurrent 704 
sinopulmonary infections. The patient has typical non-immunological features consistent with STIM1 705 
deficiency including amelogenesis imperfecta resulting in complete dental clearance, anhidrosis and 706 
muscle weakness. Surprisingly, the patient had mild immunodeficiency phenotype, with relatively 707 
preserved immunological function, including appropriate responses to challenge vaccination25. 708 
Virus amplification and concentration. MHV68-GFP virus was amplified and titrated in NIH3T3 709 
cells using standard protocols. HSV-1 KOS strain was used for all in vitro experiments and HSV-1 17+ 710 
strain was used for in vivo infection experiments. Both the strains were amplified and titrated in Vero 711 
cells using standard protocols. HSV-1 17+ strain was concentrated for in vivo experiments. VSV-G 712 
pseudotyped HIV-1NL4-3 strain-GFP reporter virus was amplified and titrated in HEK293T cells using 713 
standard protocols. 714 
28 
 
RNA isolation, cDNA synthesis and Real-time quantitative PCR. Total RNA from cells harvested 715 
in TRIzol Reagent (ThermoFisher) was isolated using the Direct-zol RNA isolation kit (Zymo 716 
Research). RNA quantity and quality were confirmed with a NanoDrop ND-1000 spectrophotometer. 717 
cDNA was synthesized using 2-3 μg of total RNA using oligo(dT) primers and Maxima Reverse 718 
Transcriptase (Thermofisher Scientific). Real-time quantitative PCR was performed using iTaq 719 
Universal SYBR Green Supermix (Bio-Rad) and an iCycler IQ5 system (Bio-Rad) using gene-specific 720 
primers described in Supplementary Table 1. Threshold cycles (CT) for all the candidate genes were 721 
normalized to those for 36b4 to obtain ΔCT and further normalized to the values obtained for WT 722 
samples to obtain ΔΔCT. The specificity of primers was examined by melt-curve analysis and agarose 723 
gel electrophoresis of PCR products. Total RNA from human patient and healthy donors PBMCs and 724 
monocytes harvested was isolated using the Total RNA purification Kit (Norgen Biotek Corp.). cDNA 725 
was synthesized using 1-2 μg of total RNA using High-Capacity cDNA Reverse Transcription Kit 726 
(ThermoFisher Scientific). Real-time quantitative PCR was performed using TaqMan Universal PCR 727 
Master Mix (ThermoFisher Scientific) using FAM-MGB probes for detection of MX1 728 
(Hs00895608_m1), IFI44 (Hs00951349), IFI44L (Hs00915292_m1), IFI27 (Hs01086370_m1), ISG15 729 
(Hs00192713_m1), CXCL10 (Hs01124251_g1), RSAD2 (Hs01057264_m1), IFIT1 (Hs01675197_m1), 730 
IFI6 (Hs00242571_m1), OAS1 (Hs00973635_m1), IL6 (Hs00985639_m1), and HPRT1 731 
(Hs99999909_m1). The relative abundance of each transcript was normalized to the expression level 732 
of HPRT1 to obtain ΔCT and further normalized to the values obtained for healthy controls to obtain 733 
ΔΔCT.  734 
Cytokine measurement by ELISA. ELISA was performed on cell culture supernatants from indicated 735 
cells or serum samples harvested from mock or HSV-1-infected animals for detection of IFNβ 736 
(Biolegend, # 439407), IL-6 (ThermoFisher, # 88-7064-88) and TNF (ThermoFisher, # 88-7324-88). 737 
Serum samples obtained from healthy controls or STIM1-deficient human patient were used for 738 
detection of IFNβ (PBL Assay Science, #41410), IL-6 (ThermoFisher Scientific, # 88-7066-22) and 739 
TNF (ThermoFisher Scientific, # 88-7346-22). 740 
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Single-cell Ca2+ imaging, live-cell epifluorescence or TIRF microscopy and confocal 741 
microscopy. THP1 and Jurkat T cells were loaded at 1 x 106 cells/ml with 1 μM Fura 2-AM for 40 min 742 
at 25oC and attached to poly-L-lysine–coated coverslips. MEFs or BMDMs were grown overnight on 743 
coverslips and loaded with 1 μM Fura 2-AM for 40 min at 25oC for imaging. Intracellular [Ca2+]i 744 
measurements were performed using essentially the same methods as previously described40. For 745 
live-cell epifluorescence imaging of STING-GFP translocation kinetics, MEFs grown on coverslips 746 
were perfused with Ringer’s solution containing (in mM): 155 NaCl, 4.5 KCl, 2 CaCl2, 1 MgCl2, 10 D-747 
glucose, and 5 Na-HEPES (pH 7.4) and used for time course imaging. Cells were perfused with 748 
digitonin permeabilization buffer (50 mM HEPES, 100 mM KCl, 3 mM MgCl2, 0.1 mM DTT, 85 mM 749 
sucrose, 0.2% BSA, 1 mM ATP, 0.1 mM GTP, pH 7.0) containing 1 μM 2’,3’-cGAMP for 10 mins and 750 
then the medium was replaced with Ringer’s solution. For TIRF analysis of STIM1-YFP translocation, 751 
MEFs were plated onto coverslip bottom dishes in medium and used for experiments. Medium was 752 
replaced with Ringer’s solution and cells were treated with 1 μM thapsigargin for passive depletion of 753 
ER Ca2+ stores to monitor STIM1 translocation. TIRF microscopy was performed using an Olympus 754 
IX2 illumination system mounted on an Olympus IX51 inverted microscope using previously described 755 
methods37. Acquisition and image analysis were performed using Slidebook (Intelligent Imaging 756 
Innovations, Inc.) software and graphs were plotted using OriginPro8.5 (Originlab). For quantification 757 
of TIRF intensity across different cells, individual regions of interest were selected and data were 758 
analyzed as the ratio of fluorescence intensity at each time-point (F) to that at the start of the 759 
experiment (F0). For confocal analysis, uninfected or HSV-infected MEFs were fixed for 20 mins with 760 
2.5% PFA at room temperature, permeabilized in buffer containing PBS + 0.2% Triton X-100, blocked 761 
with same buffer containing 1% BSA and used for staining of ERGIC marker and confocal analysis. 762 
Confocal laser scanning microscopy was performed using Fluoview FV10i Confocal Microscope 763 
(Olympus), images were captured with a 60x oil objective. Images were processed for enhancement 764 
of brightness or contrast using Fluoview software. 765 
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Generation of STIM1, STIM2 and STING-deficient cells using CRISPR-Cas9 system. To generate 766 
lentiviruses for transduction, HEK293T cells were transfected with plasmid(s) encoding sgRNA and 767 
packaging vectors (pMD2.G and psPAX2, Addgene) using calcium phosphate transfection method. 768 
Lentiviruses encoding Cas9 were generated using the same technique. Culture supernatants were 769 
harvested at 48 and 72 hours post transfection and used for infection (50% of Cas9-encoding virus + 770 
50% of sgRNA-encoding virus) of MEFs, THP1 or Jurkat T cells together with polybrene (8 µg/ml) 771 
using the spin-infection method. Cells were selected with puromycin (1 µg/ml) and blasticidin (5 µg/ml) 772 
48 hours post infection. The sequences of the sgRNAs are described in Supplementary Table 1. 773 
Immunoprecipitation and immunoblotting. For immunoprecipitation, cDNA encoding full-length or 774 
fragments (a.a. 1-154 and 149-379) of FLAG-tagged STING and 6xHis-tagged STIM1 was transfected 775 
into HEK293T cells. Transfected cells (2 x 107) were lysed in lysis buffer (20 mM Tris-Cl, 2 mM EDTA, 776 
135 mM NaCl, 10% (vol/vol) glycerol, 0.5% Igepal CA-630, protease inhibitor mixture, pH 7.5) and 777 
centrifuged at 100,000 x g for 1 hour before preclearing with protein G-Sepharose. Lysates were 778 
immunoprecipitated with anti-FLAG antibody-conjugated resin for 6 hours. Immunoprecipitates were 779 
washed five times in lysis buffer and analyzed by immunoblotting. For immunoblot analyses, cells 780 
were lysed in RIPA buffer (10 mM Tris-Cl, 1% Triton X-100, 0.1% SDS, 140 mM NaCl, 1 mM EDTA, 781 
0.1% sodium deoxycholate, and cOmplete Protease Inhibitor Cocktail [Sigma-Aldrich], pH 8.0) and 782 
centrifuged to remove debris. Samples were separated on 8-10% SDS-PAGE. Proteins were 783 
transferred to nitrocellulose membranes and subsequently analyzed by immunoblotting with relevant 784 
antibodies. For dithiobis succinimidyl propionate (DSP) crosslinking, MEFs or HEK293T cells were left 785 
untreated or treated with 0.125, 0.25, 0.5, or 1.0 mM of DSP for 1 hour on ice, followed by quenching 786 
with 20 mM Tris-Cl, pH 7.5. Cells were lysed in SDS loading dye under non-reducing conditions 787 
(without β-Mercaptoethanol) and separated on 10% SDS-PAGE and immunoblotted for detection of 788 
indicated proteins. For endogenous immunoprecipitation, HEK293 cells were lysed in lysis buffer 789 
(same as above) and centrifuged at 100,000 x g for 1 hour before preclearing with protein G-790 
Sepharose. Lysates were incubated with 2 μg of anti-STING antibody (Cell Signaling Technologies) 791 
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overnight and subsequently with protein G-Sepharose for 2 hours. For immunoprecipitation of STING 792 
SAVI mutants with endogenous STIM1, HEK293T stably expressing FLAG-tagged human STINGWT, 793 
STINGV147M, STINGN154S or STINGV155M cDNAs were lysed in lysis buffer (same as above), centrifuged 794 
at 100,000 x g for 1 hour, pre-cleared and incubated with anti-FLAG antibody-conjugated resin 795 
overnight in lysis buffer containing 0.1% Igepal CA-630 and processed as described above. PBMCs 796 
were lysed in NP40 Lysis Buffer (VWR Life Science) containing cOmplete Protease Inhibitor Cocktail 797 
(Sigma-Aldrich) and centrifuged to remove debris. 20 μg of total protein from healthy control or patient 798 
samples was separated on a 4-12% Bis-Tris Plus Gel (ThermoFisher), transferred to polyvinylidene 799 
difluoride (PVDF) membrane and subsequently analyzed by immunoblotting with relevant antibodies.  800 
Purification of recombinant proteins from E. coli. Full-length and fragments (a.a. 1-249, 250-400, 801 
324-448, 400-600, and 600-685) of STIM1 were subcloned into pGEX4T-1 plasmid. GST fusion 802 
protein expressing transformants were grown in liquid cultures and induced with isopropyl-1-thio-β-D-803 
galactopyranoside (IPTG, 0.2 mM) at 18°C overnight. Subsequently, cells were harvested and 804 
resuspended in lysis buffer (50 mM NaH2PO4, 500 mM NaCl, 10% glycerol, pH 8.0) containing 805 
protease inhibitors and 0.5% Triton X-100. Lysates were sonicated, centrifuged to remove debris and 806 
incubated with glutathione sepharose 4B beads for 2 hrs. After washing 8 times with lysis buffer, the 807 
beads were stored in lysis buffer without Triton X-100 at -20˚C. 808 
GST pulldown analysis. cDNA encoding full-length and fragments of STING-FLAG was transfected 809 
into HEK293T cells. Transfected cells (2 x 107) were lysed in lysis buffer (20 mM Tris-Cl, 2 mM EDTA, 810 
135 mM NaCl, 10% (vol/vol) glycerol, 0.5% Igepal CA-630, protease inhibitor mixture, pH 7.5) and 811 
centrifuged at 100,000 x g for 1 hour before preclearing with protein G-Sepharose. Lysates were 812 
incubated with 20 µg of GST or GST-tagged fragments of STIM1 for 18 hours in binding buffer (0.5% 813 
Igepal CA-630, 20 mM Tris-HCl, 100 mM NaCl, 2 mM EDTA, 10% glycerol, protease inhibitors, pH 814 
7.5). Pulldown samples were washed five times with lysis buffer and analyzed by immunoblotting for 815 
indicated proteins. 816 
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HSV infection in mice. Age and gender-matched control (Stim1fl/fl or Orai1fl/fl), Stim1fl/flLyz2-cre or 817 
Orai1fl/flLyz2-cre mice were intravenously injected with 1 x 107 pfu of HSV-1 17+ strain. The viability of 818 
the infected mice was monitored for 10 days. Mouse serum was collected at indicated times after 819 
infection for measurement of serum cytokine by ELISA.  820 
Statistical analysis. Statistical analysis was performed using the Origin2018b software (OriginLab, 821 
Northampton, MA, USA). Data are presented as mean ± s.e.m. For all dataset, normality and 822 
homogeneity of variance were evaluated by Shapiro-Wilk test and Levene test respectively, to ensure 823 
that the assumptions inherent to parametric significance testing were not violated. Statistical 824 
significance to compare two quantitative groups was evaluated using two-tailed/unpaired t-test. When 825 
multiple groups and/or multiple condition comparisons were necessary, one-way or two-way ANOVA 826 
was performed followed by a Tukey HSD post-hoc test. Statistical comparison of multiple counts in 827 
contingency tables was performed using Chi-square test followed by pairwise analysis of differences 828 
as post-hoc test. A critical value for significance of P < 0.05 was used throughout the study, and 829 
statistical thresholds of 0.05, 0.005 as well as 0.0005 are indicated in the figures by asterisks (see 830 
legends for details). 831 
 832 
Data availability 833 
The data that support the findings of this study are available from the corresponding authors upon 834 
request. The manuscript describing clinical phenotype of STIM1 patient is available from OSR 835 
Preprints (https://doi.org/10.31219/osf.io/4duxt). 836 
 837 
References 838 
37. Srikanth, S. et al. A novel EF-hand protein, CRACR2A, is a cytosolic Ca2+ sensor that 839 
stabilizes CRAC channels in T cells. Nat Cell Biol 12, 436-446 (2010). 840 
 841 
38. Gwack, Y. et al. Hair loss and defective T- and B-cell function in mice lacking ORAI1. Mol Cell 842 
Biol 28, 5209-5222 (2008). 843 
33 
 
 844 
39. Stetson, D.B. & Medzhitov, R. Recognition of cytosolic DNA activates an IRF3-dependent 845 
innate immune response. Immunity 24, 93-103 (2006). 846 
 847 
40. Srikanth, S., Jung, H.J., Ribalet, B. & Gwack, Y. The intracellular loop of Orai1 plays a central 848 
role in fast inactivation of Ca2+ release-activated Ca2+ channels. J Biol Chem 285, 5066-5075 849 
(2010). 850 
  851 
L M N
0
2
4
6
R
an
ge
 L
 M
 N
AL AM AN
0.0
0.4
0.8
R
an
ge
 AL
 AM
 AN
* 
X Y
0
20
40
Ra
ng
e
 X
 Y
IL6 AJ
0
2
4
6
Ra
ng
e
 IL6
 AJ
IFNb AH
0
4
8
12
R
an
ge
 IFNb
 AH
Rest-IFNb M
0
10
20
R
an
ge
 Rest-IFNb
 M
S T
0
10
20
Ra
ng
e
 S
 T
AB AC
0
5
10
15
M
X2
 AB
 AC
0
400
800
12000
16000
R
an
ge
Figure 1
a
c
Mx1
0
5
10
15
Mx2
0
5
10
15
Irf7
0
5
10
15
Ccl2
0
3
6
m
R
N
A 
(re
la
tiv
e)
MEFs
100
WT Stim1-/-
STIM1
37
b-actin
(KDa)
0
10
20
Il6
WT Stim1-/-
Orai1-/-
Ifn
b1
m
R
N
A 
(re
la
tiv
e)
0
0 200 400 600 800
0.4
0.8
1.2
M
ea
n 
(C
tl 
M
EF
s)
A Control Orai1 KO
 STIM1 KO
R
at
io
 (3
40
/3
80
) 1 µM TG
0  Ca2+ 20 Ca2+
600 
0.4
0 200 
Time (sec)
1.2 
800 400 
MEFs:
WT
Orai1-/-
Stim1-/-0.8
0.4
0.8
0P
ea
k-
ba
sa
l r
at
io
* 
WT Stim1-/-
Orai1-/-
0
10
20
WT      Stim1-/-
Ifnb1
75
STIM1
37
b-actin
WT sg#2 sg#3
THP1 cells
(KDa)
e
d
STIM1-/-
Ifnb1
0
4
8
12
Il6
0
2
4
6
m
R
N
A 
(re
la
tiv
e) WT
Stim1-/-
37
75
STIM1
b-actin
WT
(KDa)
IF
N
-b
(p
g/
m
l)
0
20
40
WT Stim1-/-
MEFsb
PMA
0
40
800
12000
IF
N
-b
(p
g/
m
l)
P = 2.69*10-5
P = 0.007
- - +      +
WT  
STIM1-/-
160
THP1 cells
f
Stim1-/-
BMDMs
Y Z
0
5
10
15
Ra
ng
e
** **
AE AF
0
5
10
15
M
X2
**
AG2 AG3
0
3
6
M
X2
 AG2
 AG3
**
**
* *
AJ AK AL AM AN AO AP
0
2
4
6
Ra
ng
e
AS AT AU AV AW AX AY
0
1
2
3
Ra
ng
e
m
R
N
A 
(re
la
tiv
e)
WT
0
2
4
6
IFNB1
STIM1-/-
+STIM1
WT
0
1
2
3
IL6
STIM1-/-
WT
sg#2
sg#3
STIM1-/-
+STIM1
STIM1-/-
*
*
*
*
*
*
*
*
2
4
**
N.S.
** **
110
100
1000
10000
R
an
ge
 AC
 AD
 AE
 AF
 AG2
 AG3
 AG4
 AG5
 AG6
 AG7
 AG8
 AG9
 AH1
 AH2
 AH3
L M N O P R S T U V W
0
5
10
15
20
Ra
ng
e
 L
 M
 N
 O
 P
 R
 S
 T
 U
 V
 W
D E F G H I J K L M N O P Q R S U
0
300
600
900
2000
3000
4000
5000
R
an
ge
K L M N
0
4
8
12
Ra
ng
e
F G H I
0
2
4
6
Ra
ng
e
AA AB
0
500
1000
1500
2000
Ra
ng
e
 AA
 AB
AH AI AJ AK AL AM AN AO
0
5
200
400
600
R
an
ge
 AH
 AI
 AJ
 AK
 AL
 AM
 AN
 AO
IFNb AS AT
0
5
1 0
0
100
200
300
R
an
ge
WT Stim1-/- Orai1-/-
Rest
cGAMP (2 h)
cGAMP (4 h)
TMEM173-/-
100
101
102
1 3
4
1
301
768
5.7
51276406
1.4
256355
0.6
0.91.0
b
0
3
3000
4000
50
MEFs:
WT Stim1-/-
Rest 2 h 4 h
6
2000
2 h 4 h
ISD pdA:dT
Ifn
b1
m
R
N
A 
(re
la
tiv
e)
9
2 h
pI:C
Ifn
b1
m
R
N
A 
(re
la
tiv
e)
a
MEFs: WT Stim1-/-c
1 2
0
40
80
120
I (
C
n
tl 
M
E
F
s)
M1
0
40
80
C
el
ls
 (%
)
WT Stim1-/-
120
Cytoplasmic
Cytoplasmic 
and nuclear
e
100
100
(kDa)
1.0 4.4 1.0 2.6
P-TBK1
TBK1
THP1MEFd
75
50
MEFs: WT Stim1-/-
DSP
0
5
10
15
IR
F3
 (D
im
er
/m
on
om
er
)
20
DSP 
IRF3: 
Dimer
Monomer
*** BMDM
1.0 3.1
f
MEFs:
WT Stim1-/-
N.S.
***
***
***
(kDa)
0
4
8
12
IL6
0
2
IFNB1
4
m
R
N
A 
(re
la
tiv
e)
STIM1: #2 #3
TMEM173-/-
75
37
37
b-actin
STING
STIM1
(-) #2 #3(-)
THP1:  WT
(kDa)
***
MEFs: resting
m
R
N
A 
(re
la
tiv
e)
0
5
10
Ifnb1
** **
0
10
20
30
Il6
** *
b-actin
WT DKO
Stim1-/-
75
37
37
STIM1
STING
b-actin
37
WT Stim1-/- WT Stim1-/- WT STIM1-/-
(kDa)
h
Figure 2
32 39
0
500
1000
1500
2000
WT Stim1-/-
***
IF
N
-b
(p
g/
m
l)
0
5
200
400
600
Resting cGAMP pI:C
THP1: 
WT STIM1-/-
IF
N
B1
m
R
N
A 
(re
la
tiv
e)
**
***
N.S.
0
1000
2000
MEFs: +cGAMP 
0
500
1000
*** ***
Ifnb1 Il6 MEFs: WT Stim1-/- DKO 
pdA:dT pI:C
0
100
200
300
IF
N
-b
(p
g/
m
l)
N.S
N.S
g
WT
Stim1-/-
DKO 
0 200 400 600 800
0.2
0.4
0.6
0.8
1.0
R
at
io
 (3
40
/3
80
) 1 µM TG
0  Ca2+ 2 mM Ca2+
60  
0.4
 20  
Time (sec)
0.8 
80  40  
0.6
WT
STIM1-/-
TMEM173-/-
DKO
0.4
0.2
0P
ea
k-
ba
sa
l r
at
io
1.0 
WT
STIM1-/-
TMEM173-/-
DKO
1.0
IFNb AW AX
0
1000
2000
Ra
ng
e
 C
 S1-/ -
 DKOIL6 BD BE
0
10
20
30
R
an
ge
 I L6
 BD
 BE IL6 BH BI
0
500
1000
Ra
ng
e
 C
 S1-/ -
 DKO
AK AL AM AN
0.0
0.2
0.4
Ra
ng
e
 AK
 AL
 AM
 AN
*** ***
6
***
***
***
***
*** ***
*** ***
N.S.
N.S.
*** N.S. N.S.
***
O P
0
400
800
1200
R
an
ge
 O
 P
BB BC BD BE
0
2
4
6
R
an
ge
 BB
 BC
 BD
 BE
BG BH BI BJ
0
500
1000
1500
Ra
ng
e
 BG
 BH
 BI
 BJ
BQ BR BS BT
0
100
200
300
R
an
ge
 BQ
 BR
 BS
 BT
IFNb O
0
100
200
300
Ra
ng
e
 IFNb
 O
c
HC Pat.
37
75
STIM1
GAPDH
WT
Stim1-/-
+STIM1
+E136X
37
STIM1
𝛽-actin
MEFs
a b
0
2
Rest
4
WT
Stim1-/-
6
m
R
N
A 
(re
la
tiv
e)
MEFs - Ifnb1
+STIM1
+E136X
0
500
1000
WT
Stim1-/-
1500
+STIM1
+E136X
+cGAMP
0
Rest
4
WT
Stim1-/-
m
R
N
A 
(re
la
tiv
e)
MEFs – Il6
+STIM1
+E136X
0
100
200
WT
Stim1-/-
300
+STIM1
+E136X
+cGAMP
***
*
0
10
200
m
R
N
A 
(re
la
tiv
e)
400
Patient
Healthy Controls
PBMCs
e
MX1 IFI44 IFI44L IFI27 ISG15 CXCL10 RSAD2 IFIT1 IFI6 OAS1
0
20
200
400
10
Monocytes
Patient
Healthy Controls
Figure 3
IF
N
-b
(p
g/
m
l)
0
100
200
300
HCs Pat.
IL
-6
 (p
g/
m
l)
0
400
800
1200
HCs Pat.
TN
F 
(p
g/
m
l)
0
2000
4000
HCs Pat.
d
m
R
N
A 
(re
la
tiv
e)
(kDa)
(kDa)
75
12
20
**
***
***
***
***
***
*** ***
***
** ***
***
***
***
***
*** ***
***
P = 1.23*10-5
P = 1.41*10-11
Q R
0
2000
4000
Ra
ng
e
 Q
 R
P = 5.53*10-10
BL BM BN BO
0
4
8
12
Ra
ng
e
 BL
 BM
 BN
 BO
8
***
*** ** **
*
*
bSTING STIM1
STING
STIM1
- + - +
+ + + +
Input IP
50
37
75
150
(KDa)
- + - +
+ + + +
Input IP
**
*
a
e
N C
DD
155-180
1 136 379
ER (NTD)
600-685
Poly-KEF-hand SAM TM CC1 S/T
1-127 127-200 234-340
363-389
390-442
3
Cytoplasmic (CTD)
340-379
CTT
2
ER Cytoplasmic
N C
STING
STIM1
f
342-448 (CAD)
*
*
*
*
*
*
a-FLAG (STING)
37
25
20
15
FL
NTD
CTD
Vec
FL
NTD
CTD
Vec
Input IP
a-His (STIM1)
100
(KDa)
STIM1
STING:
FL
NTD
CTD
c
STING STIM1 Merge
0.67±0.08
IB: His (STIM1)
D a ta  2
0 .0 0
0 .2 5
0 .5 0
0 .7 5
1 .0 0
1 .2 5
Legend
Legend
D a ta  1
0 .0 0
0 .2 5
0 .5 0
0 .7 5
1 .0 0
1 .2 5
Legend
Legend
IB: Flag (STING)
STING
STIM1
- - + +
+ + + +
- - + +
+ + + +
TG - + - + - + - +
Input IP
IB: Flag (STING)
STING
STIM1
- - + +
+ + + +
- - + +
+ + + +
cGAMP - + - + - + - +
Input IP
IB: His (STIM1)
Fo
ld
 c
ha
ng
e
0
0.5
1.0
Rest TG RestcGAMP
IgG
STING
STIM1
Calnexin
37
75
100
Input STING Ab
dIP
(KDa)
Figure 4
* *
040
80
120
% T
ran
slo
cat
ion
AI
 Complete
 Partial
 None
STIM1-/-
**
Figure 5
STIM1-/-
WT
Stim1-/-
b Time – 0 min 11 min 30 min
0 10 20 30 40
1.0
1.1
1.2
1.3
M
ea
n 
(C
nt
lM
EF
s)
A (Time(mins))
W
T
STING-GFP ERGIC Merge
St
im
1-
/- R
es
tin
g
W
T
W
T
St
im
1-
/-
H
SV
 –
4 
hr
s
a
HSV (hr) 0
0
40
80
C
el
ls
 s
ho
w
in
g 
ST
IN
G
 tr
an
sl
oc
at
io
n 
(%
)
None   
Partial   
Complete
120
1 2 43
0 10 20 30
1.0
1.1
1.2
Time (mins)
DF
/F
0
40
1.3
WT
Stim1-/-
*
WT S1-/- WT S1-/- WT S1-/- WT S1-/- WT S1-/-
125 181 169 114 109102 94 69
70
93
*********
0
4
8
12
16
4
8
1
Full-length a.a.1-249 a.a.400-600
IF
N
-L
uc
(fo
ld
 c
ha
ng
e)
STIM1: None
N.S. N.S.
a.a.250-400 a.a.600-685
16 cGAMP stimulation
** ** **
0
50
100
150
R
an
ge
40
80
120
Full-length a.a.1-249
IF
N
-L
uc
(fo
ld
 c
ha
ng
e)
STIM1:
0
None
N.S.
N.S.
Poly I:C stimulation
**
*
0
20
200
400
600
Ra
ng
e
ORF29 AZ
0.0
0.4
0.8
1.2
R
an
ge
 ORF29
 AZAY GFP
0.0
0.5
1.0
1.5
R
an
ge
AL AM AN AO AQ
0
20
40
60
R
an
ge
 AL
 AM
 AN
 AO
 AQ
b MHV68
ORF29
m
R
N
A 
(re
la
tiv
e)
MHV68
ORF57
MHV68
GFP
0
0.4
0.8
1.2
a Ifnb1 
0
20
40
60
m
R
N
A 
(re
la
tiv
e)
0.5
1.0
1.5
0
MEFs: 
WT
Stim1-/-
HSV-1GFP
**
d
0
2
200
400
600
0
20
40
500
1000
BMDM:
WT
Stim1-/-
HSV (MOI) 0 1 10 0 1 10
m
R
N
A 
(re
la
tiv
e) Ifnb1 Il6 
0 2 4 6 0 2 4 6 (h)
WT Stim1-/-
P-IRF3
IRF3
50
50
(KDa)
HSV (MOI) 0 0.1
MEFs: 
WT
Stim1-/-
c
0.1
Ratio:
THP1 HSV-GFP (MOI 10)e
WT STIM1-/-
(sg#2)
1.0
1.8
7.9
14.1
1.3
21.4
26.8
10.0
37 b-actin
Figure 6
** **
ORF57 BB
0.0
0.4
0.8
1.2
R
an
ge
 ORF57
 BB
**
GFP BD
0.0
0.4
0.8
1.2
R
an
ge
 GFP
 BD
***
**
**
**
AH AI AJ AK AL AM AN AO
0
20
40
500
1000
Ra
ng
e
**
**
**
0
10
20
30
Ra
ng
e
 Cntl - Rest
 Cntl HSV
 U
 S1#2Rest
 S1#2HSV
 X
 S1#3Rest
 S1#3HSVN O P Q R S T
0
4
8
12
Ra
ng
e
AB AC AD AE AF
0.0
0.4
0.8
1.2
R
an
ge
 AB
 AC
 AD
 AE
 AF
f
0 50K 100K 150K 200K 250K
SSC-H
0
102
103
104
105
G
FP
-A
0 50K 100K 150K 200K 250K
SSC-H
0
102
103
104
105
G
FP
-A
0 50K 100K 150K 200K 250K
SSC-H
0
102
103
104
105
G
FP
-A
0 50K 100K 150K 200K 250K
SSC-H
0
102
103
104
105
G
FP
-A
0 50K 100K 150K 200K 250K
SSC-H
0
102
103
104
105
G
FP
-A
0 50K 100K 150K 200K 250K
SSC-H
0
102
103
104
105
G
FP
-A
0 50K 100K 150K 200K 250K
SSC-H
0
102
103
104
105
G
FP
-A
0 50K 100K 150K 200K 250K
SSC-H
0
102
103
104
105
G
FP
-A
0 50K 100K 150K 200K 250K
SSC-H
0
102
103
104
105
G
FP
-A
11.1 1.65 1.85
WT STIM1-/- sg#2 STIM1-/- sg#3
G
FP
SSC
THP1:
WT 
sg#2 
sg#3
8
12
HIV (MOI)
%
 G
FP
+ 
ce
lls
AZT
2
+ 
2
-
m
R
N
A 
(re
la
tiv
e)
WT sg#2 sg#3
0
10
20
30
THP-1:
Mock  
HSV-1
IFNB1 
WT
0
0.4
1.2
0.8
HSV-1 GFP
sg#2 sg#3
** **
*
**
** **
1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5
0
200
400
2000
4000
se
ru
m
 IF
N
b
L3
 Control
 STIM1 KO
1.0 1.5 2.0 2.5
0
20000
40000
60000
 I
 K
I (
W
T)
H
0 2 4 6 8 10
0
50
100
B
A
a
0
50
100
S
ur
vi
va
l (
%
)
0 2 4 6 8 10
Stim1fl/flLyz2-cre (N=9)
Stim1fl/fl (N=12)
b c
d
0
2
4
V
iru
s 
tit
er
 (x
 1
04
)
6
Stim1fl/flLyz2-cre
Stim1fl/fl
0
200
600
S
er
um
 IL
-6
(p
g/
m
l)
400
800
HSV (h) - 1.5
0
200
600
S
er
um
 T
N
F
(p
g/
m
l)
400
0
20
400
S
er
um
 IF
N
-b
(p
g/
m
l)
2000
400
1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5
0
200
400
600
800
 Control
 STIM1 KO
se
ru
m
 IL
-6
W8 3.0 6.0 HSV (h) - 1.5 3.0 6.0HSV (h) - 1.5 3.0 6.0
1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5
0
200
400
600
se
ru
m
 T
N
F
K3
 Control
 STIM1 KO
Stim1fl/flLyz2-cre
Stim1fl/fl
*
Time (d)
0 2 4 6 8 10
0
50
100
F 
(C
on
tro
l)
E (Days)
0
50
100
S
ur
vi
va
l (
%
)
0 2 4 6 8 10
Orai1fl/flLyz2-cre (N=6)
Orai1fl/fl (N=6)
Time (d)
Figure 7
0 2 4 6 8 10
80
90
100
H
 (C
nt
rl 
B
od
y 
w
t)
G0 2 4 6 8 10
80
90
100
B
od
y 
w
ei
gh
t (
%
)
Orai1fl/fl (N=6)
Orai1fl/flLyz2-cre (N=6)
Time (d)
0 2 4 6 8 10
80
90
100
B
od
y 
w
ei
gh
t (
%
)
0 2 4 6 8 10
80
90
100
B
A
Stim1fl/fl (N=12)
Stim1fl/flLyz2-cre (N=9)
*
Time (d)
***
**
**
***
*
**
* ***
**
*
** *
